Latest in Vaccines & Immunology

prnewswire.com
96 words

ImmunoGenesis to Present IND-Enabling Development Progress and Therapeutic Potential of IMGS-203, a Novel STING Agonist, at SITC 2026 Annual Meeting

Nov 04, 2026, 13:30 ET Friday, November 6, 2026 12:15 – 1:45 PM MT PCC-North Building – Lower Level Exhibition Halls 4-5-6 Akash Boda, PhD, ImmunoGenesis Saturday, November 7, 2026 12:53 – 1:01 PM MT 204b: Rapid Oral – Clinical 2 PCC-West Building – 300 Level – 301BC About IMGS-203IMGS-203 is a novel STING agonist being developed by ImmunoGenesis as a cancer…

prnewswire.com
321 words

ImmunoGenesis Announces Two Publications Highlighting the Potential of IMGS-203, a Novel Stimulator of Interferon Genes (STING) Agonist, to Overcome Tumor Immune Resistance and Enhance Antitumor Efficacy in Combination with a Cytotoxic Dual-specific PD-L1/PD-L2 Antibody

ImmunoGenesis Announces Two Publications Highlighting the Potential of IMGS-203, a Novel Stimulator of Interferon Genes (STING) Agonist, to Overcome Tumor Immune Resistance and Enhance Antitumor Efficacy in Combination with a Cytotoxic Dual-spec PR Newswire HOUSTON, Nov. 5, 2026 /PRNewswire/ -- ImmunoGenesis, a clinical-stage…

Vaccines & Immunology

mRNA platforms, boosters, monoclonals, and immune‑system science.

  • 18 Tracked terms
  • Last 30 days Feed window
Search within this topic Ask AI about this topic All topics

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.